In a related editorial comment, Paolo Boffetta, M.D., M.P.H., associate director for population sciences at The Tisch Cancer Institute and chief of the Division of Cancer Prevention and Control of the at Mount Sinai in New York, addressed whether the increased risk of cancer in
this group of heart failure patients warranted additional screening beyond what was recommended for the general public.
Not exact matches
«Among both
groups,
patients taking Entresto had a 20 % or greater reduction in cardiovascular death or
heart failure hospitalization compared to those taking enalapril,» Novartis said in a statement, citing conclusions based on analysis
of data from the PARADIGM - HF study.
I chose cardiology, and specifically
heart failure, because I wanted to work in a subspecialty where I could care for a
group of patients over time, in my case
patients with chronic
heart disease.
- The results are also significant in that the
group included different kinds
of patients, some
of whom had
heart failure, coronary disease, and ventricular extrasystole at the same time.
They found that
patients from this
group who required admission to intensive or critical care units after surgery were more likely to have a history
of chronic obstructive pulmonary disease, congestive
heart failure, coronary artery disease, chronic kidney disease, or suffering blood loss
of more than 1,000 milliliters during surgery or requiring vasopressors (medications that raise low blood pressure) during surgery.
This
group of researchers previously looked at increased risk
of cancer among
heart failure patients and showed a 70 percent increase in risk.
Looking at the components
of the primary outcome separately, only hospitalizations, specifically for
heart failure, had a significantly lower incidence for those taking spironolactone compared to placebo, with 206
patients (12.0 percent) in the spironolactone
group undergoing hospitalization versus 245
patients (14.2 percent) in the placebo
group.
Hospitalized
heart failure patients in all age
groups within the study and with all levels
of ejection fraction had significantly lower rates
of survival after five years and a higher risk
of re-hospitalization than people in the United States without
heart failure.
After an average follow - up time
of 43 months, 105
patients or 17 percent in the DEFER
group and 109 or 18 percent in the standard treatment
group met the primary endpoint, a composite
of death from any cause, hospitalization for
heart failure, a second
heart attack, and unplanned repeat angioplasty, a nonsignificant difference.
In the gut
of patients with
heart failure, important
groups of bacteria are found less frequently and the gut flora is not as diverse as in healthy individuals.
Patients with a history of breast cancer or lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs — compared with a similar group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific
Patients with a history
of breast cancer or lymphoma were more than three times as likely to develop
heart failure — a condition in which the
heart can't pump enough blood to meet the body's needs — compared with a similar
group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific
patients who did not have cancer, according to data being presented at the American College
of Cardiology's 67th Annual Scientific Session.
In a randomized investigation
of the impact
of berberine in
patients with weakened
hearts and congestive
heart failure (CHF), there was an increase in
heart strength and a decrease in measures
of CHF in those assigned to the
group taking berberine.